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As of May 2016, the Journal of Psychopharmacology will fully 
adopt Neuroscience-based Nomenclature (NbN) for all publica-
tions and correspondence. In this, we join many other leading jour-
nals in our field, including European Neuropsychopharmacology, 
Biological Psychiatry, CNS Spectrums, European Psychiatry, 
International Journal of Neuropsychopharmacology, Journal of 
Clinical Psychopharmacology, Neuropsychopharmacology, 
Pharmacopsychiatry, World Journal of Biological Psychiatry and 
others that will also recommend the use of NbN. This decision has 
been ratified by the British Association for Psychopharmacology 
(BAP) council.
For the Journal of Psychopharmacology and the BAP, 
this step marks the output of a process that we have been 
involved in developing with the European College of 
Neuropsychopharmacology (ECNP). Part of the impetus to this 
initiative came from an editorial in Journal of Psychopharmacology 
back in 2009 (Nutt, 2009). Most of the vital background data col-
lecting and organisation of the knowledge base has been done by 
a BAP member, Dr Sue Wilson.
Under the leadership of the ECNP in 2008, a taskforce for psy-
chotropic nomenclature composed of representatives from five 
international organisations: the ECNP, American College of 
Neuropsychopharmacology, Asian College of Neuropsy-
chopharmacology, International College of Neuropsychop-
harmacology and International Union of Basic and Clinical 
Pharmacology. The group tasked itself ‘to examine ways of 
improving the current nomenclature in psychopharmacology’. 
Specifically, the new nomenclature was to (a) be based on contem-
porary scientific knowledge, (b) help clinicians to make informed 
choices when working out the next ‘pharmacological step’, (c) 
provide a system that does not conflict with the use of medications 
and (d) be future proof to accommodate new types of compounds. 
An initial proposal (Zohar et al., 2014) was discussed in the scien-
tific community and accordingly revised (Zohar et al., 2015). It is 
this revised system that Journal of Psychopharmacology will use.
NbN is a pharmacologically driven system. In this, it is scien-
tifically precise and extensible: new drug targets or modes of 
action can be easily added to the system once accepted by the 
scientific community. It is fairly comprehensive: at the present 
time, it includes 108 compounds which span the great majority of 
what is currently used in the practice of psychopharmacology. 
However, this very precision requires of authors and readers to 
adjust some well-worn habits: for example, use of the terms ‘sec-
ond-generation’ or ‘atypical antipsychotic’, or even more so a 
group reference such as ‘anxiolytics’ referring to a group of 
substances with quite heterogeneous receptor targets and mode 
of action. From an editor’s point of view, we realize that this will 
pose some additional challenges for our authors, but we believe 
that readers and ultimately the field will benefit greatly – first, by 
the self-imposed terminology precision itself, and second, by 
sometimes making it clear where gaps in our knowledge still 
exist, especially when the modes of action of drugs with relation-
ship to our evolving understanding of the neurobiology of mental 
illness are concerned (Millan et al., 2015).
Using NbN will require authors to clarify their meaning when 
they use a term for a drug. To ease the transition, Journal of 
Psychopharmacology will adopt NbN in stages: the first, effec-
tive as of May 2016, requires authors to define their usage, in the 
paper, of a term such as ‘antipsychotics’ using NbN at the point 
that it first appears in the main text of the paper. Furthermore, to 
make all new papers searchable by NbN, the NbN nomenclature 
of the substances that the paper covers has to be added to the 
keywords of the paper. To this end, we are dropping our previous 
limitation (of five) for keywords and have added a specific sub-
category NbN to the keyword finder.
The new keywords include 11 pharmacological domains and 
10 modes of action which are the building stones of NbN. It will 
make this process easier for authors and readers searching for one 
of our publications.
How does NbN work in practice? To ‘translate’ between old 
and new nomenclature, the easiest and recommended way is to 
use the approved app, which is available on the project’s website 
(http://nbnomenclature.org/), as well as in the software reposito-
ries of the various platforms for which it is available. On this 
website, there is a special tag – For Authors. A link to these 
resources is also now included in our Instructions For Authors.
The NbN effort is still in its infancy. Some necessary steps, 
such as the inclusion of paediatric psychopharmacology and neu-
ropharmacology in domains such as epilepsy are already being 
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worked on and will be included in the nomenclature in the near 
future. Most importantly, we believe that a clearer understanding 
of pharmacology will greatly benefit translational neuroscience 
and the discovery of new treatments for brain disorders.
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Table 1. Neuroscience-based Nomenclature – NbN Glossarya.
Former terminology NbN – Pharmacological based Drugs 
Indication based Pharmacology Mode of actionb
Antidepressant Drugs for depression  
(TCA) norepinephrine reuptake inhibitor (NET) desipramine
 norepinephrine, serotonin reuptake inhibitor (NET and SERT) protriptyline,lofepramine, amoxapine, 
nortriptyline
 serotonin, norepinephrine reuptake inhibitor (SERT and NET) imipramine, dosulepin
 serotonin reuptake inhibitor (SERT) clomipramine
 serotonin, norepinephrine MM; reuptake inhibitor (SERT and 
NET), receptor antagonist (5-HT2)
amitriptyline
 norepinephrine, serotonin MM; reuptake inhibitor (NET and 
SERT), receptor antagonist (5-HT2)
Doxepin
 serotonin, dopamine receptor antagonist (5-HT2 and D2) trimipramine
(MAOI) serotonin, norepinephrine, 
dopamine
enzyme inhibitor (MAO-A and -B) isocarboxazid, phenelzine
 reversible enzyme inhibitor (MAO-A) moclobemide
 MM; enzyme inhibitor (MAO-A and 
-B), releaser (DAT, NET)
tranylcypromine
 dopamine, 
norepinephrine, serotonin
enzyme inhibitor (MAO-B and -A) selegiline
(SSRI) serotonin reuptake inhibitor (SERT) citalopram, escitalopram, fluoxetine, 
fluvoxamine, paroxetine, sertraline
(SNRI) serotonin, norepinephrine reuptake inhibitor (SERT and NET) venlafaxine, duloxetine
 norepinephrine, serotonin reuptake inhibitor (NET and SERT) milnacipran
Stimulants  
 Dopamine and 
norepinephrine
Reuptake inhibitors and release amphetamine (D) and (D,L), 
lisdexamfetamine, methylphenidate (D) and 
(D, L)
Antipsychotic 
(Neuroleptics, Major 
tranquillisers)
Drugs for psychosis  
Typical (1st 
generation)
dopamine receptor antagonist (D2) flupenthixol, fluphenazine, haloperidol, 
perphenazine, pimozide, pipotiazine, 
sulpiride, trifluoperazine, zuclopenthixol
 dopamine, serotonin receptor antagonist (D2, 5-HT2) chlorpromazine, thioridazine
Atypical (2nd 
generation)
 
 
dopamine receptor antagonist (D2) amisulpiride
dopamine, serotonin receptor antagonist (D2, 5-HT2) iloperidone, loxapine, lurasidone, olanzapine, 
perospirone, sertindole, ziprasidone, zotepine
dopamine, serotonin receptor partial agonist (D2, 
5-HT1A)
aripiprazole
 dopamine, serotonin, 
noradrenaline
receptor antagonist (D2, 5-HT2, NE 
alpha-2)
asenapine, clozapine, risperidone, 
paliperidone
 MM; receptor antagonist (D2, 
5-HT2) and reuptake inhibitor (NET)
(metabolite)
quetiapine
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Former terminology NbN – Pharmacological based Drugs 
Indication based Pharmacology Mode of actionb
Anxiolytic Drugs for anxiety  
(benzodiazepine) GABA Positive Allosteric Modulator 
(GABA-A receptor, benzodiazepine 
site)
alprazolam, chlordiazepoxide, clonazepam, 
clorazepate, diazepam, flunitrazepam, 
lorazepam, oxazepam
 serotonin receptor partial agonist (5-HT1A) buspirone
 glutamate voltage-gated calcium channel 
blocker
gabapentin, pregabalin
 histamine receptor antagonist (H1) hydroxyzine
Hypnotic Drugs for insomnia  
(benzodiazepine) GABA Positive Allosteric Modulator 
(GABA-A receptor, benzodiazepine 
site)
estazolam, eszopiclone, flunitrazepam, 
lormetazepam, midazolam, quazepam, 
temazepam, triazolam, zaleplon, zolpidem , 
zopiclone
 melatonin receptor agonist (M1, M2) melatonin, ramelteon
Mood stabilizers Drugs for relapse prevention  
 glutamate voltage-gated sodium and calcium 
channel blocker
carbamazepine, oxcarbazepine
 glutamate voltage-gated sodium channel 
blocker
lamotrigine
 glutamate yet to be determined valproate
 enzyme interactions lithium
aThe glossary includes only the psychotropics relevant to former terminology. Newer psychotropics not included here could be found in NbN by their name.
bMM (Multi-Modal)=more than one mode of action.
Table 1. (Continued)
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